News · 26 weeks28+20%
2026-04-192026-10-11
Mix1290d
- Other10(83%)
- Offering1(8%)
- Insider1(8%)
Latest news
25 items- PRDaxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights: Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administratorsOperational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac careExecutive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026) OAK RIDGE, Tenn., Oct. 15,
- PRDaxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026New Clinical Studies Validate BVA™ Technology in High-Acuity Heart Failure Populations to Enhance Care OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting. Strong clinician engagement at the conference underscored the need for Daxor’s next-generation blood volume analysis (BVA™) radiopharmaceutical diagnostic system, driven by its streamlined workflow, rapid result delivery, and industry-leading accuracy exceeding 95%. Daxor highlighted
- PRDaxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026Making its ASN debut, Daxor’s BVA™ technology delivers precise volume measurement to optimize fluid management and improve complex kidney care. Key Highlights: Commercial Presence: Daxor exhibiting at Booth #390 during ASN Kidney Week 2026 in Denver, CO (October 21–25, 2026). Clinical Focus: Highlighting Blood Volume Analysis (BVA) to address critical fluid overload, cardiorenal syndrome, and dialysis volume management challenges. Global Reach: Engaging with international nephrology leaders to advance data-driven precision medicine for patients with renal disease. OAK RIDGE, Tenn., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume meas
- SECAmendment: SEC Form 40-8F-2/A filed by Daxor Corporation40-8F-2/A - DAXOR CORP (0000027367) (Filer)
- PRDaxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management. Key Highlights: Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA™) designed for rapid clinical adoption across hospital systems and outpatient clinicsClinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements in complex heart failure, LVAD, and total artificial heart patientsOn-Site Demonstrations: Daxor participating in HFSA’s dedicated Device Day and exhibiting at Booth #803 in Phoenix, AZ (October 9–1
- SECAmendment: SEC Form N-CEN/A filed by Daxor CorporationN-CEN/A - DAXOR CORP (0000027367) (Filer)
- PRDaxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth ConferenceOak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026. Management will host one-on-one and small group meetings with investors. For more information about the event or questions about registration, interested parties should reach out to their contacts at Lake Street. Interested investors may also contact Bret Shapiro at CORE IR either by calling 1-516-222-2560 or emailing brets@coreir.com. Sign up to rec
- INSIDERChief Medical Officer Jefferies John was granted 2,451 units of Daxor Common Stock, increasing direct ownership by 10% to 26,008 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- PRDaxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder LetterOak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "It’s still Day 1." — Jeff BezosThat's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our clinical data, our acquisition of our supplier, Isotex Diagnostics, our capital raise — has been about building the launch pad, not the destination. The real growth is still in front of us, and the
- SECSEC Form N-CSR filed by Daxor CorporationN-CSR - DAXOR CORP (0000027367) (Filer)
- SECSEC Form N-PX filed by Daxor CorporationN-PX - DAXOR CORP (0000027367) (Filer)
- PRDaxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in KansasCommercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics. The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood volume measurements wit
- PRDaxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, TexasDaxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™). The premier global event for autonomic disorders will take place from July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas. This year’s conference theme, "Piece by
- INSIDERChief Financial Officer Michel Robert J was granted 12,000 units of Daxor Common Stock, increasing direct ownership by 57% to 33,050 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERChief Executive Officer Feldschuh Michael Richard was granted 30,000 units of Daxor Common Stock, increasing direct ownership by 14% to 243,694 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERChief Scientific Officer Feldschuh Jonathan Adam was granted 25,000 units of Daxor Common Stock, increasing direct ownership by 46% to 78,908 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Goudie Joy S.4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Cremisi Henry D.4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Feuer Edward4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Desrosiers Caleb4 - DAXOR CORP (0000027367) (Issuer)
- SECSEC Form 8-K filed by Daxor Corporation8-K - DAXOR CORP (0000027367) (Filer)
- SECAmendment: SEC Form 40-8F-2/A filed by Daxor Corporation40-8F-2/A - DAXOR CORP (0000027367) (Filer)
- SECSEC Form DEF 14A filed by Daxor CorporationDEF 14A - DAXOR CORP (0000027367) (Filer)
- PRDaxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume MonitorNew Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia OAK RIDGE, TN, June 02, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,635,917 B2, titled "Remote Blood Volume Monitor." The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient's absolute blood volume status after an initial baseline measurement. By integrat
- SECSEC Form NT NPORT-P filed by Daxor CorporationNT NPORT-P - DAXOR CORP (0000027367) (Filer)
DXR FAQ
5 questionsWhat does Daxor Corporation do?
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood...Where does DXR stock trade?
Daxor Corporation (DXR) is listed on AMEX.What sector and industry is DXR in?
Daxor Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to DXR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare DXR side-by-side with any of them on Quantisnow.How can I track DXR on Quantisnow?
Quantisnow aggregates Daxor Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DXR to receive live email and push alerts on every new disclosure.